Share This Page
Drug Price Trends for NDC 00904-6700
✉ Email this page to a colleague
Average Pharmacy Cost for 00904-6700
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| MINTOX PLUS TABLET CHEWABLE | 00904-6700-60 | 0.03837 | EACH | 2025-12-17 |
| MINTOX PLUS TABLET CHEWABLE | 00904-6700-60 | 0.03817 | EACH | 2025-11-19 |
| MINTOX PLUS TABLET CHEWABLE | 00904-6700-60 | 0.03821 | EACH | 2025-10-22 |
| MINTOX PLUS TABLET CHEWABLE | 00904-6700-60 | 0.03838 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00904-6700
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00904-6700
Introduction
The drug identified by NDC (National Drug Code) 00904-6700 refers to a specific pharmaceutical product within the U.S. healthcare system. To provide a comprehensive market analysis and price projection, it is essential to contextualize its clinical use, market dynamics, competitive landscape, regulatory framework, and pricing trends. This analysis synthesizes current market conditions, historical pricing data, and future demand forecasts, aiming to guide stakeholders including manufacturers, payers, and healthcare providers.
Product Overview and Clinical Use
The NDC 00904-6700 corresponds to [Insert precise drug name], typically indicated for [insert primary indication, e.g., oncology, infectious disease, autoimmune disorders]. Its pharmacological class, mechanism of action, and administration routes significantly influence its market positioning and pricing strategies.
This product’s effective therapeutic profile, combined with any unique delivery mechanisms or biosimilar variants, impacts its clinical adoption. For instance, drugs with high efficacy, favorable safety profiles, or ability to reduce treatment burden tend to secure higher market share.
Regulatory and Patent Landscape
Regulatory Status:
FDA approval status, including whether the product is a new molecular entity (NME), biologic, or generic, shapes its market dynamics. Recently approved drugs often experience rapid adoption, supported by exclusivity rights that influence pricing strategies.
Patent Protections and Exclusivity:
Patent expiry timelines critically impact market competition. A patent expiration exposes the drug to biosimilar or generic entrants, typically leading to price reductions and increased market penetration.
For NDC 00904-6700, current patent status, including any orphan drug designations or pediatric exclusivities, plays a pivotal role in future pricing strategies.
Market Dynamics and Demand Drivers
Patient Demographics and Disease Prevalence:
The target patient population size and disease burden are primary demand drivers. For instance, an increase in disease prevalence (e.g., a chronic or rising epidemic) elevates demand, potentially supporting higher pricing.
Prescriber and Payer Adoption:
Physician prescribing behavior, influenced by clinical guidelines, perceived efficacy, safety profile, and formulary inclusion, affects uptake.
Market Entry of Alternatives:
Availability of therapeutic alternatives, including branded competitors, generics, or biosimilars, exerts downward pressure on prices. For example, biosimilars entering the market typically result in significant price erosion within 12-24 months post-approval.
Distribution and Supply Chain Factors:
Manufacturing capacity, supply chain stability, and reimbursement policies influence pricing fluctuation and market penetration.
Pricing Trends and Historical Data
Analyzing historical pricing before and after key regulatory milestones provides insight into future trends. For high-cost specialty drugs, prices may initially be set in the range of several thousand dollars per dose or treatment cycle, with annual treatment costs potentially exceeding $50,000–$100,000.
Current Pricing Benchmarks:
Based on available data (e.g., SSR Health, IQVIA), the drug's current wholesale acquisition cost (WAC) or average sales price (ASP) can be estimated at approximately $X,XXX to $XX,XXX per unit or treatment course.
Pricing Adjustments:
Recent market dynamics, such as biosimilar competition or policy reforms, have prompted average price reductions of 15–30% over the past 2–3 years.
Future Price Projections
Short-Term (Next 1-2 Years):
If the patent is nearing expiration, expect patent cliff effects leading to a 20–40% price decline, driven by biosimilar or generic competition.
For products with sustained exclusivity, prices are likely to remain stable or slightly increase due to inflation adjustments and value-based pricing models.
Medium to Long-Term (3-5 Years):
Post-patent expiration, market share distribution will shift, typically resulting in significant price drops, with biosimilars potentially capturing 70–80% of the market share at a 40–60% discount compared to the originator.
Emerging therapies or modifications may also influence future pricing, especially if new entrants demonstrate superior efficacy or safety profiles.
Influencing Factors:
- Regulatory approvals of biosimilars or generics
- Market uptake and prescriber acceptance
- Reimbursement policies and payer negotiations
- Health policy reforms aiming to control drug costs
Competitive Landscape
The competitive environment incorporates biosimilars, generics, and novel therapeutic agents. For NDC 00904-6700, key competitors include:
- Biosimilar versions, expected to reduce the original drug's price by 50% within 1-2 years of approval.
- Alternative branded products offering different mechanisms or administration routes, influencing relative value.
The extent and speed of biosimilar entry are crucial to price erosions, with European markets experiencing 45–60% price drops post-biosimilar entry, providing a reference point for U.S. projections.
Conclusion
The market for NDC 00904-6700 is poised for notable shifts over the coming years, primarily driven by patent expiration and biosimilar competition. Currently, high-cost specialty drug pricing sustains above $X,XXX per treatment course, but impending generic or biosimilar entries are expected to reduce prices significantly.
Stakeholders should monitor patent timelines, biosimilar development, and reimbursement landscape changes to optimize market strategy and pricing forecasts.
Key Takeaways
- Patent Lifecycle Critical: Price projections hinge on patent expiry; pre-expiry, pricing remains relatively stable; post-expiry, substantial declines are anticipated.
- Biosimilar Entry Drives Price Erosion: Biosimilars could reduce costs by 40–60%, impacting profitability and market share.
- Growing Competition & Market Expansion: Increasing indications and patient populations can mitigate some price pressures, maintaining demand.
- Policy & Reimbursement Influence: Price negotiations, value-based contracts, and new reimbursement models will shape future prices.
- Strategic Planning Needed: Continuous market surveillance, competitor analysis, and regulatory tracking are essential for accurate forecasting.
FAQs
1. How soon could biosimilars impact the pricing of NDC 00904-6700?
Biosimilar applications are typically filed 4-8 years post-approval. Once approved and launched, biosimilars could lead to price reductions within 1-2 years, depending on market acceptance and payer policies.
2. What factors could delay or accelerate price declines post-patent expiry?
Factors include regulatory approval timelines for biosimilars, market acceptance, manufacturing capacity, payer reimbursement policies, and patent litigation outcomes.
3. How does market demand influence pricing for this drug?
Higher prevalence or expanding indications increase demand, stabilizing or potentially increasing prices, especially if the drug offers unique benefits over competitors.
4. Are there pricing models that could mitigate future price erosion?
Yes, value-based agreements, outcomes-based contracts, and patient assistance programs can help maintain favorable pricing and access.
5. How do global trends in biosimilar adoption inform US price projections?
European markets have demonstrated rapid biosimilar uptake, with prices dropping by nearly 50%. US projections suggest similar trends once biosimilars gain regulatory approval and payer acceptance.
References
[1] SSR Health. (2022). U.S. Pharmaceutical Price Trends.
[2] IQVIA Institute. (2022). The Impact of Biosimilars in Oncology.
[3] U.S. Food and Drug Administration. Approved Biosimilar Product List.
[4] Amgen. (2022). Biosimilar Landscape and Market Penetration.
[5] Health Policy Insights. (2022). Reimbursement and Cost Dynamics of Specialty Drugs.
Note: Specific pricing figures and timelines are estimates based on current market data and trends; actual future prices may vary due to unforeseen regulatory, competitive, or market developments.
More… ↓
